Niamah Alaa Kareem, Al-Sahlany Shayma Thyab Gddoa, Verma Deepak Kumar, Shukla Rakesh Mohan, Patel Ami R, Tripathy Soubhagya, Singh Smita, Baranwal Deepika, Singh Amit Kumar, Utama Gemilang Lara, Chávez González Mónica L, Alhilfi Wissal Audah Hassan, Srivastav Prem Prakash, Aguilar Cristobal Noe
Department of Food Science, College of Agriculture, University of Basrah, Basra City, Iraq.
Agricultural and Food Engineering Department, Indian Institute of Technology Kharagpur, Kharagpur 721302, West Bengal, India.
Heliyon. 2024 Aug 29;10(17):e37054. doi: 10.1016/j.heliyon.2024.e37054. eCollection 2024 Sep 15.
Modern cancer diagnostics and treatment options have greatly improved survival rates; the illness remains a major cause of mortality worldwide. Current treatments for cancer, such as chemotherapy, are not cancer-specific and may cause harm to healthy cells; therefore, it is imperative that new drugs for cancer be developed that are both safe and effective. It has been found that lactic acid bacteria (LAB) have the potential to produce bacteriocins, which could potentially offer a promising alternative for cancer treatment. They have been shown in several studies to be effective against cancer cells while having no effect on healthy cells. More research is needed to fully understand the potential of LAB bacteriocins as anti-cancer medicines, to find the appropriate dose and delivery route, and to conduct clinical trials to evaluate the effectiveness and safety of the products in human patients, as is suggested by this work. Furthermore, LAB bacteriocins may evolve into a significant new class of anti-cancer drugs and food products. Patients with cancer may have a safe and effective alternative treatment option in the form of anti-cancer foods and drugs. Therefore, the aim of this study is to provide an in-depth analysis of the recent breakthroughs and potential future technical advancements of significant bacteriocins that are produced by LAB, how these bacteriocins function, and how these bacteriocins may be utilized as an anti-cancer agent. In addition, the current analysis emphasizes the significant constraints and boundaries that bacteriocins face when they are used as an anti-cancer factor.
现代癌症诊断和治疗方法极大地提高了生存率；然而，这种疾病仍是全球主要的死亡原因。目前的癌症治疗方法，如化疗，并非针对癌症特异性，可能会对健康细胞造成损害；因此，开发既安全又有效的新型抗癌药物势在必行。已发现乳酸菌（LAB）有产生细菌素的潜力，这可能为癌症治疗提供一种有前景的替代方法。多项研究表明，它们对癌细胞有效，而对健康细胞无影响。正如这项研究所示，需要更多研究来全面了解乳酸菌细菌素作为抗癌药物的潜力，找到合适的剂量和给药途径，并进行临床试验以评估这些产品在人类患者中的有效性和安全性。此外，乳酸菌细菌素可能会发展成为一类重要的新型抗癌药物和食品。癌症患者可能会有以抗癌食品和药物形式存在的安全有效的替代治疗选择。因此，本研究的目的是深入分析乳酸菌产生的重要细菌素的最新突破和未来潜在的技术进步、这些细菌素的作用方式以及它们如何被用作抗癌剂。此外，当前的分析强调了细菌素作为抗癌因子时所面临的重大限制和界限。
